Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Choose the starting dose from the Cockcroft-Gault CrCl table for the exact indication. Separate columns cover combination therapy, post-transplant maintenance or MDS, and follicular or marginal-zone lymphoma.
Limits and monitoring
Dialysis has a separate row with dosing after the session on dialysis days. Verify cycle days and blood counts before applying a schedule.
Before use
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 41, posted Aug 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Renal guidance: 2.6 Recommended Dosage for Patients with Renal Impairment / 8.6 Renal Impairment
Choose the starting dose from the Cockcroft-Gault CrCl table for the exact indication. Separate columns cover combination therapy, post-transplant maintenance or MDS, and follicular or marginal-zone lymphoma. Dialysis has a separate row with dosing after the session on dialysis days. Verify cycle days and blood counts before applying a schedule.
Source revision: DailyMed SPL version 41, posted Aug 06, 2026 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Revlimid - product and source limitations
Dialysis has a separate row with dosing after the session on dialysis days. Verify cycle days and blood counts before applying a schedule.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
U.S. product labeling / DailyMed · Selected U.S. lenalidomide capsule label. MM=myeloma; MCL=mantle-cell lymphoma; FL=follicular lymphoma; MZL=marginal-zone lymphoma; MDS=myelodysplastic syndromes.
Renal method: Cockcroft-Gault creatinine clearance in mL/min Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Renal dose table - keep the indication-specific cycle
CrCl
MM/MCL combination
FL/MZL combination
MM post-transplant maintenance or MDS
30-60 mL/min
10 mg once daily
10 mg once daily
5 mg once daily
Below 30, without dialysis
15 mg every other day
5 mg once daily
2.5 mg once daily
Below 30, requiring dialysis
5 mg once daily
5 mg once daily
2.5 mg once daily
On dialysis days, administer after dialysis. Apply these doses within the indicated treatment cycle, not an invented continuous schedule.
For MM combination therapy at CrCl 30-60, the label permits considering 15 mg after two cycles if 10 mg was tolerated without dose-limiting toxicity. Subsequent changes depend on indication and tolerability.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
Renal guidance: 2.6 Recommended Dosage for Patients with Renal Impairment / 8.6 Renal Impairment
Choose the starting dose from the Cockcroft-Gault CrCl table for the exact indication. Separate columns cover combination therapy, post-transplant maintenance or MDS, and follicular or marginal-zone lymphoma. Dialysis has a separate row with dosing after the session on dialysis days. Verify cycle days and blood counts before applying a schedule.
RDM74-revlimid-official-1 · Source locator: Renal guidance: 2.6 Recommended Dosage for Patients with Renal Impairment / 8.6 Renal Impairment
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
